UOC
SLNO

UBS O'Connor’s Soleno Therapeutics SLNO Stock Holding History

UBS O'Connor’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,362
Closed -$868K – 430
2025
Q2 		$868K Sell
10,362
-6,660
-39% -$498K 0.02% 241
2025
Q1 		$1.22M Buy
17,022
+9,045
+113% +$440K 0.03% 168
2024
Q4 		$359K Sell
7,977
-7,559
-49% -$392K 0.01% 304
2024
Q3 		$784K Buy
15,536
+536
+4% +$25.7K 0.02% 303
2024
Q2 		$612K Buy
+15,000
New +$636K 0.02% 353

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

UBS O'Connor's SLNO Position: Q3 2025 in Review

UBS O'Connor sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 10,362 shares — an estimated $868K sold.

UBS O'Connor first reported a position in SLNO in Q2 2024 and held it in 5 quarters. The position peaked at $1.22M in Q1 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • UBS O'Connor reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 10,362 Soleno Therapeutics shares in Q3 2025, an estimated $868K.
  • UBS O'Connor first reported a position in Soleno Therapeutics in Q2 2024 and held it in 5 quarters.
  • UBS O'Connor's Soleno Therapeutics position peaked at $1.22M in Q1 2025.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.